livingmed biotech

TLDR

LivingMed Biotech develops an oral vaccine for highly pathogenic avian influenza (bird flu) targeting a $10 billion+ market.

Overview

LivingMed Biotech's mission is to develop and commercialize the world's first oral vaccine for avian influenza, combining breakthrough science with practical delivery methods. The company aims to simplify disease prevention for poultry producers, reduce economic losses, and mitigate zoonotic risks by addressing limitations of traditional vaccines that are difficult to produce, transport, and administer.